ACCESS and ACCESS II studies fully enrolled; topline data from both studies anticipated by year-end 2025 Oral small molecule amylin receptor agonist (ACCG-2671) Investigational New Drug (IND)-enabling ...

Morgan Stanley analyst Terence Flynn maintained a Buy rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR – Research Report) today and ...

Fintel reports that on February 28, 2025, William Blair initiated coverage of Structure Therapeutics Inc. - Depositary ...

Citizens JMP lowered the firm’s price target on Structure Therapeutics (GPCR) to $87 from $91 and keeps an Outperform rating on the shares.

William Blair started coverage on shares of Structure Therapeutics (NASDAQ:GPCR – Free Report) in a research note published on Friday, Marketbeat Ratings reports. The brokerage issued an outperform ...

AbbVie will pay up to $2.2 billion to develop Danish drugmaker Gubra’s obesity drug. AI takes center stage at HIMSS ...

OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on the development of novel ...

In trading on Wednesday, shares of Structure Therapeutics Inc (Symbol: GPCR) entered into oversold territory, hitting an RSI reading of 29.0, after changing hands as low as $19.61 per share.

Spyre Therapeutics' innovative combination therapy approach targets multiple inflammatory pathways. Learn why SYRE stock is a Buy.